Shopping Cart 0
Cart Subtotal
AED 0

Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia-Pipeline Review, H2 2018, provides an overview of the Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Homozygous Familial Hypercholesterolemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 4, 2, 2 and 1 respectively.

Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Homozygous Familial Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Homozygous Familial Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Homozygous Familial Hypercholesterolemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 4

Homozygous Familial Hypercholesterolemia (HoFH)-Overview 5

Homozygous Familial Hypercholesterolemia (HoFH)-Therapeutics Development 6

Homozygous Familial Hypercholesterolemia (HoFH)-Therapeutics Assessment 10

Homozygous Familial Hypercholesterolemia (HoFH)-Companies Involved in Therapeutics Development 18

Homozygous Familial Hypercholesterolemia (HoFH)-Drug Profiles 24

Homozygous Familial Hypercholesterolemia (HoFH)-Dormant Projects 82

Homozygous Familial Hypercholesterolemia (HoFH)-Discontinued Products 83

Homozygous Familial Hypercholesterolemia (HoFH)-Product Development Milestones 84

Appendix 96


List Of Figure

List of Figures

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Akcea Therapeutics Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Daewoong Co Ltd, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Gemphire Therapeutics Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Innovent Biologics Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by LipimetiX Development Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Madrigal Pharmaceuticals Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Novelion Therapeutics Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by RegenxBio Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by The Medicines Company, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Dormant Projects, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutic Products under Development, Key Players in Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Homozygous Familial Hypercholesterolemia (HoFH) Pipeline Overview, Homozygous Familial Hypercholesterolemia (HoFH) Pipeline, Homozygous Familial Hypercholesterolemia (HoFH) Pipeline Assessment


Companies

Akcea Therapeutics Inc

Daewoong Co Ltd

Gemphire Therapeutics Inc

Innovent Biologics Inc

LipimetiX Development Inc

Madrigal Pharmaceuticals Inc

Novelion Therapeutics Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

The Medicines Company

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Homozygous Familial Hypercholesterolemia-Pipeline Review, H2 2018, provides an overview of the Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Homozygous familial hypercholesterolemia is a genetic disorder which is caused due to mutation from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain and sores on the toes that do not heal. Treatment includes diet changes and statin drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Homozygous Familial Hypercholesterolemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Homozygous Familial Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Homozygous Familial Hypercholesterolemia (HoFH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 4, 2, 2 and 1 respectively.

Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Homozygous Familial Hypercholesterolemia (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Homozygous Familial Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Homozygous Familial Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Homozygous Familial Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Homozygous Familial Hypercholesterolemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Homozygous Familial Hypercholesterolemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Homozygous Familial Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 4

Homozygous Familial Hypercholesterolemia (HoFH)-Overview 5

Homozygous Familial Hypercholesterolemia (HoFH)-Therapeutics Development 6

Homozygous Familial Hypercholesterolemia (HoFH)-Therapeutics Assessment 10

Homozygous Familial Hypercholesterolemia (HoFH)-Companies Involved in Therapeutics Development 18

Homozygous Familial Hypercholesterolemia (HoFH)-Drug Profiles 24

Homozygous Familial Hypercholesterolemia (HoFH)-Dormant Projects 82

Homozygous Familial Hypercholesterolemia (HoFH)-Discontinued Products 83

Homozygous Familial Hypercholesterolemia (HoFH)-Product Development Milestones 84

Appendix 96


List Of Figure

List of Figures

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Homozygous Familial Hypercholesterolemia (HoFH), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Akcea Therapeutics Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Daewoong Co Ltd, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Gemphire Therapeutics Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Innovent Biologics Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by LipimetiX Development Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Madrigal Pharmaceuticals Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Novelion Therapeutics Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by RegenxBio Inc, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Pipeline by The Medicines Company, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Dormant Projects, H2 2018

Homozygous Familial Hypercholesterolemia (HoFH)-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Homozygous Familial Hypercholesterolemia (HoFH) Therapeutic Products under Development, Key Players in Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Homozygous Familial Hypercholesterolemia (HoFH) Pipeline Overview, Homozygous Familial Hypercholesterolemia (HoFH) Pipeline, Homozygous Familial Hypercholesterolemia (HoFH) Pipeline Assessment


Companies

Akcea Therapeutics Inc

Daewoong Co Ltd

Gemphire Therapeutics Inc

Innovent Biologics Inc

LipimetiX Development Inc

Madrigal Pharmaceuticals Inc

Novelion Therapeutics Inc

Regeneron Pharmaceuticals Inc

RegenxBio Inc

The Medicines Company